BACKGROUND AND OBJECTIVES: Although hyperglycemia is thought to increase the generation of advanced glycation end products (AGEs), studies have not shown a consistent relationship between abnormal glucose metabolism and serum AGEs. We investigated the relationship between a dominant serum AGE, N-carboxymethyl-lysine (CML), and glucose metabolism. SUBJECTS AND METHODS: Serum CML, fasting plasma glucose, and glucose tolerance were measured in 755 adults in the Baltimore Longitudinal Study of Aging. Fasting plasma glucose was categorized as normal (< or = 99 mg/dL), impaired (100-125 mg/dL), and diabetic (> 125 mg/dL). Two-hour plasma glucose on oral glucose tolerance testing was categorized as normal (< or = 139 mg/dL), impaired (140-199 mg/dL), and diabetic (> or = 200 mg/dL). RESULTS: The proportion of adults with normal, impaired, and diabetic fasting plasma glucose was 73.8%, 22.9%, and 2.9%, respectively, and the proportion with normal, impaired, and diabetic 2-hour plasma glucose was 73.1%, 19.2%, and 7.7%, respectively. Serum CML (microg/mL) was not associated with abnormal fasting plasma glucose (Odds Ratio [O.R.] 0.60, 95% Confidence Interval [C.I.] 0.15-2.36, P = 0.47) in a multivariate, ordered logistic regression model, adjusting for age, race, gender, body mass index, and chronic diseases. Serum CML (microg/mL) was associated with abnormal 2-hour plasma glucose on glucose tolerance testing (O.R. 0.15, 95% C.I. 0.04-0.63, P = 0.009) in a multivariate, ordered logistic regression model, adjusting for the same covariates. CONCLUSIONS: Elevated CML, a dominant AGE, was not associated with elevated fasting plasma glucose and was associated with a reduced odds of abnormal glucose tolerance in older community-dwelling adults.
BACKGROUND AND OBJECTIVES: Although hyperglycemia is thought to increase the generation of advanced glycation end products (AGEs), studies have not shown a consistent relationship between abnormal glucose metabolism and serum AGEs. We investigated the relationship between a dominant serum AGE, N-carboxymethyl-lysine (CML), and glucose metabolism. SUBJECTS AND METHODS: Serum CML, fasting plasma glucose, and glucose tolerance were measured in 755 adults in the Baltimore Longitudinal Study of Aging. Fasting plasma glucose was categorized as normal (< or = 99 mg/dL), impaired (100-125 mg/dL), and diabetic (> 125 mg/dL). Two-hour plasma glucose on oral glucose tolerance testing was categorized as normal (< or = 139 mg/dL), impaired (140-199 mg/dL), and diabetic (> or = 200 mg/dL). RESULTS: The proportion of adults with normal, impaired, and diabetic fasting plasma glucose was 73.8%, 22.9%, and 2.9%, respectively, and the proportion with normal, impaired, and diabetic 2-hour plasma glucose was 73.1%, 19.2%, and 7.7%, respectively. Serum CML (microg/mL) was not associated with abnormal fasting plasma glucose (Odds Ratio [O.R.] 0.60, 95% Confidence Interval [C.I.] 0.15-2.36, P = 0.47) in a multivariate, ordered logistic regression model, adjusting for age, race, gender, body mass index, and chronic diseases. Serum CML (microg/mL) was associated with abnormal 2-hour plasma glucose on glucose tolerance testing (O.R. 0.15, 95% C.I. 0.04-0.63, P = 0.009) in a multivariate, ordered logistic regression model, adjusting for the same covariates. CONCLUSIONS: Elevated CML, a dominant AGE, was not associated with elevated fasting plasma glucose and was associated with a reduced odds of abnormal glucose tolerance in older community-dwelling adults.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: B O Boehm; S Schilling; S Rosinger; G E Lang; G K Lang; R Kientsch-Engel; P Stahl Journal: Diabetologia Date: 2004-07-17 Impact factor: 10.122
Authors: Richard D Semba; Jeffrey C Fink; Kai Sun; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci Journal: Eur J Nutr Date: 2008-11-24 Impact factor: 5.614
Authors: Richard D Semba; Stefania Bandinelli; Kai Sun; Jack M Guralnik; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2009-08-13 Impact factor: 5.562
Authors: Casper G Schalkwijk; Alexi Baidoshvili; Coen D A Stehouwer; Victor W M van Hinsbergh; Hans W M Niessen Journal: Biochim Biophys Acta Date: 2004-03-22
Authors: Richard D Semba; Mary Frances Cotch; Vilmundur Gudnason; Gudny Eiríksdottir; Tamara B Harris; Kai Sun; Ronald Klein; Fridbert Jonasson; Luigi Ferrucci; Debra A Schaumberg Journal: JAMA Ophthalmol Date: 2014-04-01 Impact factor: 7.389
Authors: R D Semba; A Ang; S Talegawkar; C Crasto; M Dalal; P Jardack; M G Traber; L Ferrucci; L Arab Journal: Eur J Clin Nutr Date: 2011-07-27 Impact factor: 4.016
Authors: Nadim Naser; Andrzej S Januszewski; Bronwyn E Brown; Alicia J Jenkins; Michael A Hill; Timothy V Murphy Journal: Front Physiol Date: 2013-03-11 Impact factor: 4.566